Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort Study (CZECH-PSMA)
2026年5月19日 更新者：doc. MUDr. Otakar Čapoun, Ph.D., FEBU、General University Hospital, Prague
Prostate cancer is the second most common malignancy worldwide and the fifth leading cause of male cancer-related mortality.
Approximately 15% of localized cases are classified as high-risk for biochemical recurrence.
These patients frequently harbour occult metastases undetected by conventional imaging (CT and bone scintigraphy).
Consequently, PSMA PET has revolutionized primary staging and is strongly recommended by EAU guidelines.
In the Czech Republic, a transition toward a "PSMA-first" pathway is evident, where molecular imaging increasingly replaces conventional modalities.
This "stage-migration" identifies a new cohort of miN1/M1 patients previously classified as having localized disease.
However, PSMA PET is a resource-demanding modality and not yet universally available.
To optimize its utility, identifying which combinations of routinely available parameters predict metastatic disease and characterizes this new cohort is essential.
Furthermore, real-world evidence regarding early oncological outcomes within this PSMA-only framework is limited.
This multicentre cohort study aims to define a multiparametric predictive model for PSMA-detected metastases and evaluate the real-world therapeutic trajectories and follow-up outcomes of this newly defined high-risk population.
Integrating clinical, biological, and molecular data, seeks to refine patient selection and provide a longitudinal perspective on the "PSMA-first" diagnostic era.
研究概览
研究类型
观察性的
注册 (估计的)
400
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
取样方法
非概率样本
研究人群
Persons: Male patients aged ≥ 18 years with histologically confirmed prostate adenocarcinoma. Place: The Czech Republic, including patients diagnosed and treated in Urological and ahiliated Nuclear Medicine Departments.
Time period (Study Window): January 1, 2016 to December 31, 2025, capturing the transition toward molecular imaging in primary staging.
Selection Criteria: Patients with histologically confirmed high-risk prostate cancer according to EAU guidelines who underwent primary staging with PSMA PET within the study window.
描述
Inclusion Criteria
Male patients will be included if:
- Male patients aged ≥ 18 years with histologically confirmed prostate adenocarcinoma,
- high-risk disease defined as ISUP GG ≥ 4 and/or PSA ≥ 20 ng/ml and/or clinical stage assessed by DRE ≥ cT2c,
- PSMA PET performed for primary staging within study window.
Exclusion Criteria
Patients with:
- definitive local treatment (e.g., radical prostatectomy or radiation therapy) or systemic treatment (e.g., androgen deprivation therapy) administered prior to primary staging with PSMA PET,
- low or intermediate-risk PCa as defined by failing to meet any of the inclusionary high-risk parameters,
- incomplete or fragmented medical records that preclude the accurate extraction of primary staging parameters (PSA, ISUP GG, clinical T-stage) or PSMA PET results (miN/miM status),
- active malignancy requiring systemic treatment at the time of PSMA PET.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
High-risk localized or locally advanced PCa before treatment
|
PSMA PET with different the use radiotracers as primary staging of high risk localized or locally advanced PCa
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Area Under the Receiver Operating Characteristic (AUC ROC) [scale 0 to 1] of multiparametric model for miN1 and/or miM1 on PSMA (prostate specific membrane antigen) PET (positron emission tomography) according to PROMISE (prostate cancer) V2 criteria.
大体时间：Data collected at the time of result of PSMA PET/CT imaging, approximately 1 month after.
|
This predictive model aggregates heterogeneous predictors into a single numerical probability score to determine the presence of metastasis by multivariate logistical regression.
The model will include: serum PSA (prostate specific antigen) [μg/ml] and/or PSA density [μg/ml/cc], clinical T stage [T1a/b/c, T2a/b/c, T3a/b, T4], prostate biopsy ISUP GG - International Society of Urology Pathology Grade Group [1/2/3/4/5], and the presence of a cribriform growth pattern, multiparametric MRI (magnetic resonance imaging) PI-RADS (Prostate Imaging Reporting and Data System) v2.1 score [1/2/3/4/5], as well as SUVmax (maximum standardized uptake value) [g/ml] and PSMA PET total tumor volume [ml] of the primary intraprostatic lesion.
Higher scores/values indicate more aggressive disease.
|
Data collected at the time of result of PSMA PET/CT imaging, approximately 1 month after.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of miT and miN stage migration between PSMA PET (according to PROMISE V2) and final histopathology from radical prostatectomy.
大体时间：At the time of surgery (approximately 2-6 weeks post-imaging).
|
The proportion of participants whose pathological stage pT and pN differs from the molecular imaging stage miT and miN.
Upstaging: Percentage of cases where pathology reveals more advanced disease than PET (e.g., miT2 to pT3a).
Downstaging: Percentage of cases where pathology reveals less extensive disease than PET (e.g., miN1 to pN0).
Total Concordance: Percentage of cases where miT/N and pT/N are identical.
|
At the time of surgery (approximately 2-6 weeks post-imaging).
|
|
Prognostic Value of Combined Molecular and Clinicopathological Markers for Early Oncological Outcomes
大体时间：From the date of treatment with curative intent up to 10 years.
|
Evaluation of the combined predictive utility of PSMA SUVmax (maximum standardized uptake value) [g/ml] and / or phi (the Prostate Health Index) and / or the presence of a cribriform growth pattern for forecasting early oncological outocmes including biochemical persistence (defined as PSA ≥ 0.1 ng/mL at 6-8 weeks post-surgery) and biochemical recurrence (defined as two consecutive PSA values ≥ 0.2 ng/mL after radical prostatectomy or ≥ 2 ng/mL above nadir after radical radiotherapy).
The study also measures the impact of these integrated parameters on progression-free survival and overall survival.
Predictive accuracy is quantified through multivariable modeling to determine the additive value of molecular imaging over standard clinical parameters.
|
From the date of treatment with curative intent up to 10 years.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Frequency of clinical management changes based on PSMA PET/CT compared to conventional imaging
大体时间：From the date of initial conventional imaging to the initiation of the final treatment plan (approximately 4-12 weeks).
|
This measure assesses the proportion of participants whose treatment plan is modified following PSMA PET/CT staging relative to the strategy established by conventional imaging.
A management change is defined as a transition in clinical intent, such as moving from local curative therapy to systemic treatment due to the discovery of metastatic disease.
The study records the rate at which molecular imaging findings lead to a change in the final management decision compared to standard-of-care imaging.
|
From the date of initial conventional imaging to the initiation of the final treatment plan (approximately 4-12 weeks).
|
|
Rate of interobserver agreement between local and central expert reviews using standardized PROMISE V2 criteria
大体时间：From the date of initial imaging until the completion of centralized review (approximately 3 months).
|
The level of consistency between local site investigators and central expert reviewers is assessed through the comparison of PSMA PET/CT molecular staging findings.
Agreement is quantified using Cohen's kappa coefficient to evaluate the reproducibility of the PROMISE V2 criteria.
|
From the date of initial imaging until the completion of centralized review (approximately 3 months).
|
|
Predictive accuracy of preoperative markers for adverse pathological features at radical prostatectomy
大体时间：At the time of surgery (approximately 2-6 weeks post-imaging)
|
This measure assesses the ability of PSMA PET findings (SUVmax of prostate and seminal vesicles and / or total PSMA volume) and clinical parameters (PSA-D and / or cribriform pattern) to predict the presence of high-risk disease features in the final surgical specimen.
Adverse pathological features are defined as the presence of pT3 (pathological T stage 3) and final ISUP (International Society of Urological Pathology) Grade Group ≥ 4, or pelvic lymph node metastasis (pN1).
The predictive performance is reported using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity to quantify the diagnostic accuracy of preoperative staging compared to the gold-standard histopathology.
|
At the time of surgery (approximately 2-6 weeks post-imaging)
|
|
Rate of biochemical recurrence-free survival in the oligometastatic subgroup of this cohort primarly staged with PSMA PET
大体时间：From the date of primary treatment up to 10 years.
|
This outcome measure determines the proportion of participants in the oligometastatic subgroup who remain free of biochemical recurrence following primary treatment.
Biochemical recurrence is defined as the occurrence of two consecutive PSA values ≥ 0.2 ng/mL.
By aggregating these clinical, diagnostic, and oncological parameters, the study evaluates the total impact of PSMA PET/CT on the standard of care and its influence on subsequent clinical management.
|
From the date of primary treatment up to 10 years.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2016年1月1日
初级完成 (估计的)
2026年12月1日
研究完成 (估计的)
2027年12月1日
研究注册日期
首次提交
2026年4月2日
首先提交符合 QC 标准的
2026年5月19日
首次发布 (实际的)
2026年5月27日
研究记录更新
最后更新发布 (实际的)
2026年5月27日
上次提交的符合 QC 标准的更新
2026年5月19日
最后验证
2026年5月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.